An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Neratinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 11 May 2012
At a glance
- Drugs Neratinib (Primary)
- Indications Breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- 11 May 2012 Company (Puma Biotechnology) added and actual patient number changed from 28 to 27 as reported by ClinicalTrials.gov.
- 11 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.